17:54 , Nov 2, 2016 |  BC Week In Review  |  Company News

Ganymed, Astellas deal

Astellas will acquire cancer company Ganymed for €422 million ($459.4 million) in cash. Ganymed shareholders are also eligible for up to €860 million ($936.2 million) in undisclosed milestones tied to the development of Ganymed's lead...
07:00 , Oct 28, 2016 |  BC Extra  |  Company News

Astellas acquiring Ganymed

Astellas Pharma Inc. (Tokyo:4503) is acquiring cancer company Ganymed Pharmaceuticals AG (Mainz, Germany) for EUR 422 million ($459.4 million) in cash. Ganymed shareholders are also eligible for up to EUR 860 million ($936.2 million) in...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

IMAB362: Phase II data

Top-line data from the open-label, European Phase II FAST trial in 161 patients with CLND18.2-positive advanced or recurrent gastric or gastroesophageal junction cancer who have not received previous chemotherapy showed that a loading dose of...
01:02 , Jun 7, 2016 |  BC Extra  |  Clinical News

Latest data show survival benefit for Ganymed's IMAB362

Updated data presented at the American Society of Clinical Oncology (ASCO) meeting showed IMAB362 from Ganymed Pharmaceuticals AG (Mainz, Germany) plus chemotherapy led to longer overall survival (OS) and progression-free survival (PFS) than chemotherapy alone...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

IMAB362: Completed Phase II enrollment

Ganymed completed enrollment of 210 patients who have not received previous chemotherapy in the open-label, international Phase II FAST trial comparing IMAB362 every 3 weeks plus chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX) vs. EOX...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Clinical News

IMAB362: Phase IIa data

Data from 21 patients with advanced gastroesophageal cancer in the per protocol (PP) population of an open-label, European Phase IIa trial showed that 600 mg/m 2 IMAB362 as monotherapy every 2 weeks for 5 cycles...
01:23 , May 28, 2014 |  BC Extra  |  Clinical News

Ganymed reports IMAB362 data for gastroesophogeal cancer

Ganymed Pharmaceuticals AG (Mainz, Germany) said IMAB362 led to a disease control rate of 48%, including four partial responses and six cases of stable disease in patients with advanced CLND18.2-positive gastroesophageal cancer. The data were...
07:00 , May 26, 2014 |  BioCentury  |  Finance

Europe's Iceberg 2014: Premier League teams

Competing in biotech's Premier League requires deep pockets, long term planning and the risk appetite to pursue novel technologies or targets that don't always pan out. BioCentury's 12th annual European Iceberg survey reveals that for...
08:00 , Nov 25, 2013 |  BioCentury  |  Finance

Venture not dead yet

A series of significant venture rounds last week pushed the money raised by private biotechs this year across the $5 billion mark, making it the 10th straight year in which the industry has crossed the...
01:56 , Nov 19, 2013 |  BC Extra  |  Financial News

Ganymed raises EUR 45 million in series E

Ganymed Pharmaceuticals AG (Mainz, Germany) raised EUR 45 million ($60.8 million) in a series E round from existing investors ATS Beteiligungsverwaltung; MIG Fond; and FCPB Gany. Ganymed's IMAB362 is in Phase II testing for gastroesophageal...